000021886 001__ 21886
000021886 005__ 20210129210813.0
000021886 0247_ $$2pmid$$apmid:22645298
000021886 0247_ $$2DOI$$a10.2967/jnumed.111.098590
000021886 0247_ $$2WOS$$aWOS:000306164600020
000021886 0247_ $$2altmetric$$aaltmetric:770359
000021886 037__ $$aPreJuSER-21886
000021886 041__ $$aeng
000021886 082__ $$a610
000021886 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000021886 1001_ $$0P:(DE-Juel1)VDB73298$$aGalldiks, N.$$b0$$uFZJ
000021886 245__ $$aAssessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI
000021886 260__ $$aNew York, NY$$bSociety of Nuclear Medicine$$c2012
000021886 264_1 $$2Crossref$$3online$$bSociety of Nuclear Medicine$$c2012-05-29
000021886 264_1 $$2Crossref$$3print$$bSociety of Nuclear Medicine$$c2012-07-01
000021886 264_1 $$2Crossref$$3print$$bSociety of Nuclear Medicine$$c2012-07-01
000021886 300__ $$a1048-1057
000021886 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000021886 3367_ $$2DataCite$$aOutput Types/Journal article
000021886 3367_ $$00$$2EndNote$$aJournal Article
000021886 3367_ $$2BibTeX$$aARTICLE
000021886 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000021886 3367_ $$2DRIVER$$aarticle
000021886 440_0 $$03621$$aJournal of Nuclear Medicine$$v7$$x0097-9058$$y53
000021886 500__ $$aRecord converted from VDB: 12.11.2012
000021886 520__ $$aThe assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) during treatment.In a prospective study, 25 patients with glioblastoma were investigated by MRI and (18)F-FET PET after surgery (MRI-/FET-1), early (7-10 d) after completion of radiochemotherapy with temozolomide (RCX) (MRI-/FET-2), and 6-8 wk later (MRI-/FET-3). Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively) were determined by region-of-interest analyses. Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-brain ratio greater than 1.6 (T(vol 1.6)) were calculated using threshold-based volume-of-interest analyses. The patients were grouped into responders and nonresponders according to the changes of these parameters at different cutoffs, and the influence on progression-free survival and overall survival was tested using univariate and multivariate survival analyses and by receiver-operating-characteristic analyses.Early after completion of RCX, a decrease of both TBR(max) and TBR(mean) was a highly significant and independent statistical predictor for progression-free survival and overall survival. Receiver-operating-characteristic analysis showed that a decrease of the TBR(max) between FET-1 and FET-2 of more than 20% predicted poor survival, with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75). Six to eight weeks later, the predictive value of TBR(max) and TBR(mean) was less significant, but an association between a decrease of T(vol 1.6) and PFS was noted. In contrast, Gd-volume changes had no significant predictive value for survival.In contrast to Gd-volumes on MRI, changes in (18)F-FET PET may be a valuable parameter to assess treatment response in glioblastoma and to predict survival time.
000021886 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems (FUEK409)$$cFUEK409$$x0
000021886 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000021886 588__ $$aDataset connected to Web of Science, Pubmed
000021886 65320 $$2Author$$aglioblastoma
000021886 65320 $$2Author$$aassessment of treatment response
000021886 65320 $$2Author$$aprognosis
000021886 65320 $$2Author$$aamino acid PET
000021886 65320 $$2Author$$aF-18-fluoroethyl-L-tyrosine (F-18-FET)
000021886 650_2 $$2MeSH$$aAdult
000021886 650_2 $$2MeSH$$aAged
000021886 650_2 $$2MeSH$$aBrain Neoplasms: radionuclide imaging
000021886 650_2 $$2MeSH$$aBrain Neoplasms: therapy
000021886 650_2 $$2MeSH$$aChemoradiotherapy
000021886 650_2 $$2MeSH$$aContrast Media
000021886 650_2 $$2MeSH$$aDisease Progression
000021886 650_2 $$2MeSH$$aDisease-Free Survival
000021886 650_2 $$2MeSH$$aFemale
000021886 650_2 $$2MeSH$$aGadolinium
000021886 650_2 $$2MeSH$$aGlioblastoma: radionuclide imaging
000021886 650_2 $$2MeSH$$aGlioblastoma: therapy
000021886 650_2 $$2MeSH$$aHumans
000021886 650_2 $$2MeSH$$aKaplan-Meier Estimate
000021886 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000021886 650_2 $$2MeSH$$aMale
000021886 650_2 $$2MeSH$$aMiddle Aged
000021886 650_2 $$2MeSH$$aNeurosurgical Procedures
000021886 650_2 $$2MeSH$$aPositron-Emission Tomography
000021886 650_2 $$2MeSH$$aPrognosis
000021886 650_2 $$2MeSH$$aProportional Hazards Models
000021886 650_2 $$2MeSH$$aProspective Studies
000021886 650_2 $$2MeSH$$aRadiopharmaceuticals: diagnostic use
000021886 650_2 $$2MeSH$$aSurvival Analysis
000021886 650_2 $$2MeSH$$aTreatment Outcome
000021886 650_2 $$2MeSH$$aTyrosine: analogs & derivatives
000021886 650_2 $$2MeSH$$aTyrosine: diagnostic use
000021886 650_7 $$00$$2NLM Chemicals$$a(18F)fluoroethyltyrosine
000021886 650_7 $$00$$2NLM Chemicals$$aContrast Media
000021886 650_7 $$00$$2NLM Chemicals$$aRadiopharmaceuticals
000021886 650_7 $$055520-40-6$$2NLM Chemicals$$aTyrosine
000021886 650_7 $$07440-54-2$$2NLM Chemicals$$aGadolinium
000021886 650_7 $$2WoSType$$aJ
000021886 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.J.$$b1$$uFZJ
000021886 7001_ $$0P:(DE-HGF)0$$aHoly, R.$$b2
000021886 7001_ $$0P:(DE-HGF)0$$aPinkawa, M.$$b3
000021886 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b4$$uFZJ
000021886 7001_ $$0P:(DE-HGF)0$$aNolte, K.W.$$b5
000021886 7001_ $$0P:(DE-HGF)0$$aKaiser, H.J.$$b6
000021886 7001_ $$0P:(DE-Juel1)VDB101468$$aFilss, C.P.$$b7$$uFZJ
000021886 7001_ $$0P:(DE-Juel1)131720$$aFink, G.R.$$b8$$uFZJ
000021886 7001_ $$0P:(DE-Juel1)131816$$aCoenen, H.H.$$b9$$uFZJ
000021886 7001_ $$0P:(DE-HGF)0$$aEble, M.J.$$b10
000021886 7001_ $$0P:(DE-HGF)0$$aPiroth, M.D.$$b11
000021886 77318 $$2Crossref$$3journal-article$$a10.2967/jnumed.111.098590$$b : Society of Nuclear Medicine, 2012-05-29$$n7$$p1048-1057$$tJournal of Nuclear Medicine$$v53$$x0161-5505$$y2012
000021886 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.111.098590$$gVol. 53$$n7$$p1048-1057$$q53<7$$tJournal of nuclear medicine$$v53$$x0161-5505$$y2012
000021886 8567_ $$uhttp://dx.doi.org/10.2967/jnumed.111.098590
000021886 909CO $$ooai:juser.fz-juelich.de:21886$$pVDB
000021886 9141_ $$y2012
000021886 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000021886 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000021886 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000021886 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000021886 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000021886 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000021886 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000021886 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000021886 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000021886 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000021886 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000021886 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000021886 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000021886 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000021886 9201_ $$0I:(DE-Juel1)INM-3-20090406$$gINM$$kINM-3$$lKognitive Neurowissenschaften$$x0
000021886 9201_ $$0I:(DE-Juel1)INM-4-20090406$$gINM$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000021886 9201_ $$0I:(DE-Juel1)INM-5-20090406$$gINM$$kINM-5$$lNuklearchemie$$x2
000021886 970__ $$aVDB:(DE-Juel1)138042
000021886 980__ $$aVDB
000021886 980__ $$aConvertedRecord
000021886 980__ $$ajournal
000021886 980__ $$aI:(DE-Juel1)INM-3-20090406
000021886 980__ $$aI:(DE-Juel1)INM-4-20090406
000021886 980__ $$aI:(DE-Juel1)INM-5-20090406
000021886 980__ $$aUNRESTRICTED
000021886 981__ $$aI:(DE-Juel1)INM-4-20090406
000021886 981__ $$aI:(DE-Juel1)INM-5-20090406